Cutaneous adverse reactions during epidermal growth factor receptor inhibitor therapy

Dominika Ragin; Magdalena Basałygo; Katarzyna Nowacka; Barbara Zegarska

doi:10.5114/dr.2018.77112

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2018
vol. 105

Send email

Copy url:

abstract:

Review paper

Cutaneous adverse reactions during epidermal growth factor receptor inhibitor therapy

Dominika Ragin

,

Magdalena Basałygo

,

Katarzyna Nowacka

,

Barbara Zegarska

Dermatol Rev/Przegl Dermatol 2018, 105, 421–433

DOI: https://doi.org/10.5114/dr.2018.77112

Online publish date: 2018/07/20

View full text Get citation

PlumX metrics:

Epidermal growth factor receptor inhibitors are medications used in the treatment of many neoplasms, including non-small cell lung cancer and colorectal cancer. Because of the expression of epidermal growth factor receptor in the epidermal cells and hair follicles, cutaneous adverse effects occur in many patients during this treatment. The most common dermatological adverse event is development of a papulopustular rash, which is usually accompanied by xerosis and pruritus. Dermatological symptoms observed during treatment with epidermal factor receptor inhibitors also include changes in the nail plate area, changes in the structure and growth of hair, hypersensitivity to ultraviolet radation and mucous membrane changes. These symptoms often significantly impair quality of life and may require a change in oncological therapy. This article summarizes available data about possible methods of preventing or treating cutaneous adverse effects of epidermal growth factor receptor inhibitors.

keywords:

Cutaneous adverse reactions during epidermal growth factor receptor inhibitor therapy

Dominika Ragin , Magdalena Basałygo , Katarzyna Nowacka , Barbara Zegarska

adverse effects, antineoplastic agents, growth factor receptor inhibitors, pruritus, acneiform eruptions

Dominika Ragin

,

Magdalena Basałygo

,

Katarzyna Nowacka

,

Barbara Zegarska